Cannabis has been used as an aphrodisiac for thousands of years. Ancient Indian Ayurvedic texts described cannabis preparations for enhancing sexual pleasure. Traditional Chinese medicine included cannabis in formulations for sexual dysfunction. In 2024, a nationally representative survey found that 44% of cannabis consumers reported using it intentionally before sex, making sexual enhancement one of the top five reasons for cannabis use in the United States.
But the relationship between cannabis and sexual function is not a simple enhancement story. It is dose-dependent, gender-specific, strain-variable, and mediated by neurochemical systems that produce genuinely opposite effects at different thresholds. The research is more interesting — and more useful — than the memes suggest.
The Endocannabinoid System and Sexual Function
The endocannabinoid system is embedded throughout the reproductive and sexual response systems in ways that researchers are still mapping. CB1 receptors are densely expressed in the hypothalamus (which regulates gonadotropin-releasing hormone), the amygdala (which processes sexual stimuli), and the nucleus accumbens (which mediates sexual reward). CB2 receptors are present in reproductive tissues in both sexes.
Anandamide, the body’s primary endocannabinoid, appears to play a direct role in the human sexual response. A 2017 study published in the Journal of Sexual Medicine found that plasma anandamide levels increased significantly during sexual arousal in healthy volunteers, peaking just before orgasm. This suggests that the endocannabinoid system does not merely influence sexual function peripherally — it is an active participant in the arousal-to-orgasm cascade.
The theoretical implication is that exogenous cannabinoids (THC, CBD) may modulate sexual response by engaging the same receptor systems that endocannabinoids naturally activate during sex. Whether this modulation is beneficial or detrimental depends on dose, timing, and individual neurobiology.
What the Surveys Show
Large-scale survey data consistently finds that cannabis users report more frequent sex, greater sexual satisfaction, and fewer sexual difficulties than non-users. But surveys are not controlled experiments, and the associations are confounded by obvious variables (cannabis users may differ from non-users in personality, risk tolerance, social context, and other factors that independently influence sexual behavior).
The most frequently cited study is a 2017 analysis of NSFG (National Survey of Family Growth) data by Dr. Michael Eisenberg at Stanford, published in the Journal of Sexual Medicine. Eisenberg analyzed responses from over 50,000 Americans and found that daily cannabis users reported approximately 20% more frequent sexual intercourse compared to never-users, after controlling for age, race, education, income, marital status, and other drug use. The association held across all demographic subgroups and both sexes.
A 2019 survey of 373 women published in Sexual Medicine found that 68% reported improved sexual experiences overall after using cannabis, with specific improvements in desire (60%), orgasm quality (53%), and reduction in pain during intercourse (40%). Women who used cannabis before sex more frequently reported satisfying orgasms compared to those who used cannabis but not before sex.
A 2020 survey of 811 cannabis users published in the Journal of Cannabis Research found that 74% of respondents reported increased sexual desire after use, 66% reported enhanced pleasure, and 70% reported more intense orgasms. However, 16% reported decreased desire at higher doses, and 9% reported difficulty with arousal — foreshadowing the dose-dependency that controlled research would later confirm.
Dose-Dependent Effects: The Biphasic Pattern
Cannabis and sex follows the same biphasic pattern that characterizes cannabis and anxiety, cannabis and creativity, and cannabis and motor function. Low doses tend to enhance. High doses tend to impair.
A 2023 study published in Psychopharmacology conducted a controlled dose-response investigation with 128 participants. Each participant consumed a standardized low dose (5mg THC), moderate dose (15mg THC), or high dose (25mg THC) before engaging in validated sexual function assessments. The results confirmed the biphasic model:
At 5mg THC, both men and women reported increased subjective arousal, heightened tactile sensitivity, and reduced sexual anxiety. At 15mg THC, women continued to report positive effects but men showed the first signs of diminished performance, including delayed ejaculation and difficulty maintaining erection in a subset of participants. At 25mg THC, both sexes reported decreased desire, increased distraction, and difficulty achieving orgasm.
The mechanism appears to involve THC’s effects on the sympathetic nervous system. Low-dose THC produces mild parasympathetic dominance — relaxation, vasodilation, reduced anxiety — which facilitates sexual arousal. High-dose THC shifts toward sympathetic activation — increased heart rate, anxiety, cognitive preoccupation — which is antagonistic to sexual function.
Additionally, THC at high doses affects the prefrontal cortex in ways that may produce “spectating” — the phenomenon of becoming cognitively detached from the sexual experience and observing oneself from an outside perspective, which is one of the most reliable inhibitors of sexual function across all contexts.
Gender Differences
The gender-specific effects of cannabis on sexual function are among the most consistent findings in the literature, and they favor women.
Women appear to derive greater sexual benefit from cannabis at a wider range of doses. Multiple studies have found that cannabis increases subjective arousal, genital blood flow, and orgasm intensity in women more consistently than in men. A 2019 gynecological survey of 452 women published in Sexual Medicine found that cannabis users reported significantly higher Female Sexual Function Index (FSFI) scores than non-users, with the largest differences in the arousal and orgasm domains.
The most likely explanation involves cannabis’s anxiolytic and muscle-relaxant properties. Sexual dysfunction in women is more frequently driven by psychological factors (anxiety, distraction, body image concerns, difficulty relaxing) than by vascular or anatomical factors. Low-dose cannabis addresses multiple psychological barriers to female arousal simultaneously — it reduces anxiety, increases present-moment focus, enhances tactile sensitivity, and promotes the parasympathetic state associated with arousal.
For women who experience pain during intercourse (dyspareunia), cannabis may have particular value. THC and CBD both have analgesic and anti-inflammatory properties, and topical cannabis products designed for vaginal application have become one of the fastest-growing segments of the legal cannabis market. While controlled clinical trials of topical cannabis for dyspareunia are limited, a 2022 observational study in the Journal of Sexual Medicine found that 72% of women using THC-containing vaginal suppositories reported significant pain reduction during intercourse.
For men, the picture is more complicated. Low-dose cannabis frequently enhances subjective experience — men report greater pleasure, more intense sensation, and feeling more connected to partners. But at moderate to high doses, THC can impair erectile function. The mechanism involves THC’s vasodilatory effects (which can actually facilitate erection at low doses) competing with anxiety-driven sympathetic activation (which impairs erection at high doses). Additionally, chronic heavy cannabis use has been associated in some studies with reduced testosterone levels, though the evidence is inconsistent and effect sizes are small.
A 2019 systematic review in the Journal of Sexual Medicine analyzed 16 studies of cannabis and male sexual function and concluded that the relationship was “complex and dose-dependent,” with low-frequency use associated with improved sexual function and high-frequency use associated with increased risk of erectile difficulties and delayed ejaculation.
Fertility Considerations
Cannabis effects on fertility deserve separate discussion from sexual function, as they operate through different mechanisms.
For men, THC has documented effects on sperm. A 2019 study published in Human Reproduction found that moderate cannabis use (less than once per week) was actually associated with higher sperm concentrations compared to never-users — a surprising finding that may reflect healthy-user confounding. However, heavy daily use has been more consistently linked to reduced sperm motility, altered morphology, and changes in seminal fluid composition. The effects appear to be reversible with cessation.
For women, the endocannabinoid system is involved in ovulation, implantation, and early pregnancy maintenance. Anandamide levels must fall within a specific range for successful embryo implantation — both too much and too little endocannabinoid signaling can disrupt implantation. Exogenous THC may disrupt this signaling, and most reproductive endocrinologists recommend discontinuing cannabis when actively trying to conceive.
During pregnancy, the evidence is clearer: THC crosses the placenta, is present in breast milk, and the American College of Obstetricians and Gynecologists recommends against cannabis use during pregnancy and lactation. This recommendation is supported by observational data linking prenatal cannabis exposure to modestly lower birth weight and potential neurodevelopmental effects, though the evidence for long-term cognitive effects remains contested.
CBD and Sexual Function
CBD (cannabidiol) influences sexual function through different mechanisms than THC. Rather than directly activating CB1 receptors, CBD modulates serotonin signaling through 5-HT1A receptor agonism, reduces anxiety, and has smooth muscle relaxant properties.
A 2022 open-label pilot study published in the Journal of Cannabis Research found that a daily 25mg CBD supplement improved self-reported sexual satisfaction in 63% of participants over an eight-week period, with the greatest improvements in individuals who reported anxiety-related sexual difficulties. The proposed mechanism is that CBD’s anxiolytic effects lower the psychological barriers to sexual function without producing the intoxication, distraction, or dose-dependent performance issues associated with THC.
CBD-infused lubricants and topical products have become increasingly popular, though rigorous clinical data on their efficacy is limited. The theoretical basis — CBD’s anti-inflammatory and vasodilatory properties applied locally to increase blood flow and reduce discomfort — is sound, but peer-reviewed efficacy data consists primarily of survey studies and case reports rather than randomized controlled trials.
Practical Implications
The research supports several actionable conclusions:
Dose is the primary variable. The difference between cannabis-enhanced sex and cannabis-impaired sex is almost entirely a function of dose. Low doses (2.5 to 7.5 mg THC) are consistently associated with positive effects. High doses (above 20 mg) are consistently associated with impairment. The sweet spot is highly individual but generally falls between 2.5 and 10 mg for most people.
Timing matters. Inhaled cannabis peaks within 5 to 15 minutes and produces effects lasting 1 to 3 hours. Edibles peak at 60 to 120 minutes with effects lasting 4 to 8 hours. For sexual use, inhaled cannabis offers more precise timing and dose control. Many users find that consuming 20 to 30 minutes before sexual activity produces the best combination of onset and duration.
Strain and cannabinoid profile matter. Products with moderate THC (10 to 18%) and some CBD content appear to produce more consistent sexual enhancement than high-THC products. Terpene profile may also play a role — limonene and linalool, which have anxiolytic properties, may support the relaxation that facilitates arousal.
Set and setting apply. Cannabis amplifies existing states. If you are relaxed, connected to your partner, and in a comfortable environment, cannabis is more likely to enhance the experience. If you are anxious, distracted, or uncomfortable, cannabis may amplify those states instead.
Gender-specific expectations are supported by data. Women are more likely to experience consistent enhancement across a wider dose range. Men benefit at low doses but face increasing risk of performance issues at moderate to high doses. Both sexes report enhanced subjective pleasure and sensation at appropriate doses.
The gap between anecdotal wisdom and clinical evidence is narrowing. What centuries of human experience suggested — that cannabis, used thoughtfully, can be a sexual enhancer — is increasingly supported by controlled research. The key word, as with most things cannabis-related, is thoughtfully.